Megan N. Michalski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Megan N. Michalski has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Bart O. Williams
Van Andel Institute
4 shared publications Bart O. Williams
Van Andel Institute, Department of Cell Biology
3 shared publications- Cassandra R. Diegel
Van Andel Research Institute
3 shared publications Zhendong A. Zhong
Center for Cancer and Cell Biology, Van Andel Institute 2 , Grand Rapids, MI 49503, USA
3 shared publications- Amy J. Koh
Department of Periodontics and Oral Medicine University of Michigan School of Dentistry Ann Arbor Michigan USA
2 shared publications Bing Zhang
Lester and Sue Smith Breast Center, Baylor College of Medicine
2 shared publications
Latest Publications
- Open Access
Deletion of the Wnt regulator Znrf3 alters bone geometry without inducing high bone mass
RNF43 and ZNRF3 are transmembrane E3 ubiquitin ligases that negatively regulate Wnt signaling by promoting ubiquitination and degradation of Frizzled receptors. Loss of either gene enhances Wnt/β-catenin signaling and has been linked to tumorigenesis. Wnt signaling is a key regulator of skeletal development and bone homeostasis, and pharmacologic activation of this pathway is an established therapy for osteoporosis. In Xenopus laevis, simultaneous disruption of rnf43 and znrf3 results in supernumerary limb formation; however, their roles in mammalian limb development and skeletal maintenance remain unclear. We demonstrate that mice homozygous for null alleles of both Rnf43 and Znrf3 do not develop supernumerary limbs. Because activation of Wnt/β-catenin signaling in osteoblasts increases bone mass, we hypothesized that osteoblast-specific deletion of Rnf43 and/or Znrf3 would produce a high-bone-mass phenotype. Instead, osteoblast-specific loss of Znrf3 resulted in age- and sex-dependent reductions in trabecular bone mass, characterized by decreased bone mineral density and bone volume fraction, reduced trabecular number, and increased trabecular separation. Cortical bone exhibited increased cross-sectional size with reduced cortical area fraction and altered structural properties, while tissue mineral density was unchanged. In contrast, deletion of Rnf43 had minimal skeletal effects, and combined deletion of both genes did not exacerbate the phenotype observed with loss of Znrf3 alone. These findings identify Znrf3 as the dominant functional paralog regulating bone architecture in mature osteoblasts and underscore the importance of evaluating skeletal geometry when modulating upstream Wnt regulators.
Open AccessDeletion of the Wnt regulator Znrf3 alters bone geometry without inducing high bone mass
RNF43 and ZNRF3 are transmembrane E3 ubiquitin ligases that negatively regulate Wnt signaling by promoting ubiquitination and degradation of Frizzled receptors. Loss of either gene enhances Wnt/β-catenin signaling and has been linked to tumorigenesis. Wnt signaling is a key regulator of skeletal development and bone homeostasis, and pharmacologic activation of this pathway is an established therapy for osteoporosis. In Xenopus laevis, simultaneous disruption of rnf43 and znrf3 results in supernumerary limb formation; however, their roles in mammalian limb development and skeletal maintenance remain unclear. We demonstrate that mice homozygous for null alleles of both Rnf43 and Znrf3 do not develop supernumerary limbs. Because activation of Wnt/β-catenin signaling in osteoblasts increases bone mass, we hypothesized that osteoblast-specific deletion of Rnf43 and/or Znrf3 would produce a high-bone-mass phenotype. Instead, osteoblast-specific loss of Znrf3 resulted in age- and sex-dependent reductions in trabecular bone mass, characterized by decreased bone mineral density and bone volume fraction, reduced trabecular number, and increased trabecular separation. Cortical bone exhibited increased cross-sectional size with reduced cortical area fraction and altered structural properties, while tissue mineral density was unchanged. In contrast, deletion of Rnf43 had minimal skeletal effects, and combined deletion of both genes did not exacerbate the phenotype observed with loss of Znrf3 alone. These findings identify Znrf3 as the dominant functional paralog regulating bone architecture in mature osteoblasts and underscore the importance of evaluating skeletal geometry when modulating upstream Wnt regulators.
- Open Access
- 1 November 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (11)
The class A repeats of LRP5 are required for normal development of bone, retinal vasculature and mammary gland in vivo
Low-density lipoprotein-related receptor 5 (LRP5) is an LDLR family member with well-defined roles in mediating Wnt signaling. Its domain structure includes four LDLR class B and three LDLR class A repeats. Class B repeats mediate binding with Wnt ligands and other effectors, while the role of the LRP5 class A repeats, known to interact with apolipoproteins within the LDLR, is unclear. Complete loss of the LRP5 gene in humans causes osteoporosis pseudoglioma, a syndrome characterized by early-onset osteoporosis and changes in retinal vascularization. We and others have previously created mice and rats completely deficient in LRP5 and reported the presence of bone and retinal vascularization defects. In this study, we created an allele of Lrp5 in mice in which the entire protein except for the class A repeats is present and expressed from the endogenous locus. Unlike in vitro studies using ectopic overexpression of LRP5, our in vivo data demonstrate that the class A repeats are essential for several normal LRP5 functions, including bone homeostasis, retinal vascularization and mammary gland development – phenotypes similar to those observed in Lrp5 null mice.
- 1 November 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (11)
Open AccessThe class A repeats of LRP5 are required for normal development of bone, retinal vasculature and mammary gland in vivo
Low-density lipoprotein-related receptor 5 (LRP5) is an LDLR family member with well-defined roles in mediating Wnt signaling. Its domain structure includes four LDLR class B and three LDLR class A repeats. Class B repeats mediate binding with Wnt ligands and other effectors, while the role of the LRP5 class A repeats, known to interact with apolipoproteins within the LDLR, is unclear. Complete loss of the LRP5 gene in humans causes osteoporosis pseudoglioma, a syndrome characterized by early-onset osteoporosis and changes in retinal vascularization. We and others have previously created mice and rats completely deficient in LRP5 and reported the presence of bone and retinal vascularization defects. In this study, we created an allele of Lrp5 in mice in which the entire protein except for the class A repeats is present and expressed from the endogenous locus. Unlike in vitro studies using ectopic overexpression of LRP5, our in vivo data demonstrate that the class A repeats are essential for several normal LRP5 functions, including bone homeostasis, retinal vascularization and mammary gland development – phenotypes similar to those observed in Lrp5 null mice.
- Open Access
- 17 February 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Loss of ZNRF3/RNF43 Unleashes EGFR in Cancer
ZNRF3 and RNF43 are closely related transmembrane E3 ubiquitin ligases with significant roles in development and cancer. Conventionally, their biological functions have been associated with regulating WNT signaling receptor ubiquitination and degradation. However, our proteogenomic studies have revealed EGFR as the protein most negatively correlated with ZNRF3/RNF43 mRNA levels in multiple human cancers. Through biochemical investigations, we demonstrate that ZNRF3/RNF43 interact with EGFR via their extracellular domains, leading to EGFR ubiquitination and subsequent degradation facilitated by the E3 ligase RING domain. Overexpression of ZNRF3 reduces EGFR levels and suppresses cancer cell growth in vitro and in vivo, whereas knockout of ZNRF3/RNF43 stimulates cell growth and tumorigenesis through upregulated EGFR signaling. Together, these data highlight ZNRF3 and RNF43 as novel E3 ubiquitin ligases of EGFR and establish the inactivation of ZNRF3/RNF43 as a driver of increased EGFR signaling, ultimately promoting cancer progression. This discovery establishes a connection between two fundamental signaling pathways, EGFR and WNT, at the level of cytoplasmic membrane receptors, uncovering a novel mechanism underlying the frequent co-activation of EGFR and WNT signaling in development and cancer.
- 17 February 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Open AccessLoss of ZNRF3/RNF43 Unleashes EGFR in Cancer
ZNRF3 and RNF43 are closely related transmembrane E3 ubiquitin ligases with significant roles in development and cancer. Conventionally, their biological functions have been associated with regulating WNT signaling receptor ubiquitination and degradation. However, our proteogenomic studies have revealed EGFR as the protein most negatively correlated with ZNRF3/RNF43 mRNA levels in multiple human cancers. Through biochemical investigations, we demonstrate that ZNRF3/RNF43 interact with EGFR via their extracellular domains, leading to EGFR ubiquitination and subsequent degradation facilitated by the E3 ligase RING domain. Overexpression of ZNRF3 reduces EGFR levels and suppresses cancer cell growth in vitro and in vivo, whereas knockout of ZNRF3/RNF43 stimulates cell growth and tumorigenesis through upregulated EGFR signaling. Together, these data highlight ZNRF3 and RNF43 as novel E3 ubiquitin ligases of EGFR and establish the inactivation of ZNRF3/RNF43 as a driver of increased EGFR signaling, ultimately promoting cancer progression. This discovery establishes a connection between two fundamental signaling pathways, EGFR and WNT, at the level of cytoplasmic membrane receptors, uncovering a novel mechanism underlying the frequent co-activation of EGFR and WNT signaling in development and cancer.
- Open Access
Loss of ZNRF3/RNF43 Unleashes EGFR in Cancer
ZNRF3 and RNF43 are closely related transmembrane E3 ubiquitin ligases with significant roles in development and cancer. Conventionally, their biological functions have been associated with regulating WNT signaling receptor ubiquitination and degradation. However, our proteogenomic studies have revealed EGFR as the protein most negatively correlated with ZNRF3/RNF43 mRNA levels in multiple human cancers. Through biochemical investigations, we demonstrate that ZNRF3/RNF43 interact with EGFR via their extracellular domains, leading to EGFR ubiquitination and subsequent degradation facilitated by the E3 ligase RING domain. Overexpression of ZNRF3 reduces EGFR levels and suppresses cancer cell growth in vitro and in vivo , whereas knockout of ZNRF3 / RNF43 stimulates cell growth and tumorigenesis through upregulated EGFR signaling. Together, these data highlight ZNRF3 and RNF43 as novel E3 ubiquitin ligases of EGFR and establish the inactivation of ZNRF3/RNF43 as a driver of increased EGFR signaling, ultimately promoting cancer progression. This discovery establishes a connection between two fundamental signaling pathways, EGFR and WNT, at the level of cytoplasmic membrane receptors, uncovering a novel mechanism underlying the frequent co-activation of EGFR and WNT signaling in development and cancer.
Open AccessLoss of ZNRF3/RNF43 Unleashes EGFR in Cancer
ZNRF3 and RNF43 are closely related transmembrane E3 ubiquitin ligases with significant roles in development and cancer. Conventionally, their biological functions have been associated with regulating WNT signaling receptor ubiquitination and degradation. However, our proteogenomic studies have revealed EGFR as the protein most negatively correlated with ZNRF3/RNF43 mRNA levels in multiple human cancers. Through biochemical investigations, we demonstrate that ZNRF3/RNF43 interact with EGFR via their extracellular domains, leading to EGFR ubiquitination and subsequent degradation facilitated by the E3 ligase RING domain. Overexpression of ZNRF3 reduces EGFR levels and suppresses cancer cell growth in vitro and in vivo , whereas knockout of ZNRF3 / RNF43 stimulates cell growth and tumorigenesis through upregulated EGFR signaling. Together, these data highlight ZNRF3 and RNF43 as novel E3 ubiquitin ligases of EGFR and establish the inactivation of ZNRF3/RNF43 as a driver of increased EGFR signaling, ultimately promoting cancer progression. This discovery establishes a connection between two fundamental signaling pathways, EGFR and WNT, at the level of cytoplasmic membrane receptors, uncovering a novel mechanism underlying the frequent co-activation of EGFR and WNT signaling in development and cancer.
- Open Access
- 26 August 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (9) , 1311
The Past, Present, and Future of Genetically Engineered Mouse Models for Skeletal Biology
The ability to create genetically engineered mouse models (GEMMs) has exponentially increased our understanding of many areas of biology. Musculoskeletal biology is no exception. In this review, we will first discuss the historical development of GEMMs and how these developments have influenced musculoskeletal disease research. This review will also update our 2008 review that appeared in BONEKey, a journal that is no longer readily available online. We will first review the historical development of GEMMs in general, followed by a particular emphasis on the ability to perform tissue-specific (conditional) knockouts focusing on musculoskeletal tissues. We will then discuss how the development of CRISPR/Cas-based technologies during the last decade has revolutionized the generation of GEMMs.
- 26 August 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (9) , 1311
Open AccessThe Past, Present, and Future of Genetically Engineered Mouse Models for Skeletal Biology
The ability to create genetically engineered mouse models (GEMMs) has exponentially increased our understanding of many areas of biology. Musculoskeletal biology is no exception. In this review, we will first discuss the historical development of GEMMs and how these developments have influenced musculoskeletal disease research. This review will also update our 2008 review that appeared in BONEKey, a journal that is no longer readily available online. We will first review the historical development of GEMMs in general, followed by a particular emphasis on the ability to perform tissue-specific (conditional) knockouts focusing on musculoskeletal tissues. We will then discuss how the development of CRISPR/Cas-based technologies during the last decade has revolutionized the generation of GEMMs.
- Open Access
- 1 February 2023
- Published by The Company of Biologists in Development
- Vol. 150 (3)
Successful therapeutic intervention in new mouse models of frizzled 2-associated congenital malformations
Frizzled 2 (FZD2) is a transmembrane Wnt receptor. We previously identified a pathogenic human FZD2 variant in individuals with FZD2-associated autosomal dominant Robinow syndrome. The variant encoded a protein with a premature stop and loss of 17 amino acids, including a region of the consensus dishevelled-binding sequence. To model this variant, we used zygote microinjection and i-GONAD-based CRISPR/Cas9-mediated genome editing to generate a mouse allelic series. Embryos mosaic for humanized Fzd2W553* knock-in exhibited cleft palate and shortened limbs, consistent with patient phenotypes. We also generated two germline mouse alleles with small deletions: Fzd2D3 and Fzd2D4. Homozygotes for each allele exhibit a highly penetrant cleft palate phenotype, shortened limbs compared with wild type and perinatal lethality. Fzd2D4 craniofacial tissues indicated decreased canonical Wnt signaling. In utero treatment with IIIC3a (a DKK inhibitor) normalized the limb lengths in Fzd2D4 homozygotes. The in vivo replication represents an approach for further investigating the mechanism of FZD2 phenotypes and demonstrates the utility of CRISPR knock-in mice as a tool for investigating the pathogenicity of human genetic variants. We also present evidence for a potential therapeutic intervention.
- 1 February 2023
- Published by The Company of Biologists in Development
- Vol. 150 (3)
Open AccessSuccessful therapeutic intervention in new mouse models of frizzled 2-associated congenital malformations
Frizzled 2 (FZD2) is a transmembrane Wnt receptor. We previously identified a pathogenic human FZD2 variant in individuals with FZD2-associated autosomal dominant Robinow syndrome. The variant encoded a protein with a premature stop and loss of 17 amino acids, including a region of the consensus dishevelled-binding sequence. To model this variant, we used zygote microinjection and i-GONAD-based CRISPR/Cas9-mediated genome editing to generate a mouse allelic series. Embryos mosaic for humanized Fzd2W553* knock-in exhibited cleft palate and shortened limbs, consistent with patient phenotypes. We also generated two germline mouse alleles with small deletions: Fzd2D3 and Fzd2D4. Homozygotes for each allele exhibit a highly penetrant cleft palate phenotype, shortened limbs compared with wild type and perinatal lethality. Fzd2D4 craniofacial tissues indicated decreased canonical Wnt signaling. In utero treatment with IIIC3a (a DKK inhibitor) normalized the limb lengths in Fzd2D4 homozygotes. The in vivo replication represents an approach for further investigating the mechanism of FZD2 phenotypes and demonstrates the utility of CRISPR knock-in mice as a tool for investigating the pathogenicity of human genetic variants. We also present evidence for a potential therapeutic intervention.
- Open Access
Dkk1 inhibition normalizes limb phenotypes in a mouse model of Fzd2 associated omodysplasia Robinow syndromes
FRIZZLED-2 (FZD2) is a transmembrane Wnt ligand receptor. We previously identified a pathogenic human FZD2 variant, encoding for a protein with a premature stop and loss of 17 amino acids. This includes a portion of the consensus DISHEVELLED binding sequence required for Wnt signal transduction. Patients with this variant exhibited FZD2-associated autosomal dominant Robinow Syndrome. To model this variant, we utilized zygote microinjection and i -GONAD-based CRISPR/Cas9-mediated genome editing to generate an allelic series in the mouse. Embryos mosaic for humanized Fzd2 W553* knock-in exhibited cleft palate and shortened limbs, consistent with FZD2 W548* patient phenotypes. We also generated two germline mouse alleles with small deletions, Fzd2 D3 and Fzd2 D4 . Homozygotes for each allele survive embryonic development at normal ratios but exhibit a highly penetrant cleft palate phenotype, shortened limbs compared to wild-type and perinatal lethality. Fzd2 D4 craniofacial tissues indicated decreased canonical WNT signaling. In utero treatment with IIIC3a (DKK inhibitor) normalized the limb lengths in Fzd2 D4 homozygotes. The in vivo replication represents an approach to further investigate the mechanism of FZD2 phenotypes and validates the utility of CRISPR knock-in mice as a tool for demonstrating pathogenicity of human genetic variants. We also present evidence for a potential therapeutic intervention.
Open AccessDkk1 inhibition normalizes limb phenotypes in a mouse model of Fzd2 associated omodysplasia Robinow syndromes
FRIZZLED-2 (FZD2) is a transmembrane Wnt ligand receptor. We previously identified a pathogenic human FZD2 variant, encoding for a protein with a premature stop and loss of 17 amino acids. This includes a portion of the consensus DISHEVELLED binding sequence required for Wnt signal transduction. Patients with this variant exhibited FZD2-associated autosomal dominant Robinow Syndrome. To model this variant, we utilized zygote microinjection and i -GONAD-based CRISPR/Cas9-mediated genome editing to generate an allelic series in the mouse. Embryos mosaic for humanized Fzd2 W553* knock-in exhibited cleft palate and shortened limbs, consistent with FZD2 W548* patient phenotypes. We also generated two germline mouse alleles with small deletions, Fzd2 D3 and Fzd2 D4 . Homozygotes for each allele survive embryonic development at normal ratios but exhibit a highly penetrant cleft palate phenotype, shortened limbs compared to wild-type and perinatal lethality. Fzd2 D4 craniofacial tissues indicated decreased canonical WNT signaling. In utero treatment with IIIC3a (DKK inhibitor) normalized the limb lengths in Fzd2 D4 homozygotes. The in vivo replication represents an approach to further investigate the mechanism of FZD2 phenotypes and validates the utility of CRISPR knock-in mice as a tool for demonstrating pathogenicity of human genetic variants. We also present evidence for a potential therapeutic intervention.
- Open Access
Generation of a New Frizzled 2 Flox Mouse Model to Clarify Its Role in Development
It is currently accepted that Wnt receptors, Frizzleds (Fzd), have high functional redundancy, making individual receptors challenging to target therapeutically. Specifically, Fzd2 is believed to be functionally redundant with Fzd1 and Fzd7, findings which were based largely on previously published global knockout mouse studies. Conversely, a Fzd2 global knockout mouse model developed by the International Mouse Phenotype Consortium (IMPC) is early embryonic lethal, suggesting Fzd2 is critical for early embryonic development. If global deletion of Fzd2 leads to early lethality, floxed models are necessary to identify tissue-specific phenotypes. We found that a previously published Fzd2 flox model does not fully delete Fzd2 function. To reconcile the contradictory findings in Fzd2 mouse models and allow for tissue-specific studies of Fzd2, we have generated a new flox model using a modified two-cell homologous recombination CRISPR approach. We demonstrated successful simultaneous insertion of two loxP sites fully surrounding the Fzd2 gene and confirmed cre-mediated recombination deletes the sequence between the loxP sites leading to a Fzd2 null allele. Preliminary studies suggest global knockouts are early embryonic lethal and full characterization of the tissue-specific effects of Fzd2 deletion is currently underway. This work suggests Fzd2 uniquely regulates development and emphasizes the importance of thorough validation of newly generated mouse models.
Open AccessGeneration of a New Frizzled 2 Flox Mouse Model to Clarify Its Role in Development
It is currently accepted that Wnt receptors, Frizzleds (Fzd), have high functional redundancy, making individual receptors challenging to target therapeutically. Specifically, Fzd2 is believed to be functionally redundant with Fzd1 and Fzd7, findings which were based largely on previously published global knockout mouse studies. Conversely, a Fzd2 global knockout mouse model developed by the International Mouse Phenotype Consortium (IMPC) is early embryonic lethal, suggesting Fzd2 is critical for early embryonic development. If global deletion of Fzd2 leads to early lethality, floxed models are necessary to identify tissue-specific phenotypes. We found that a previously published Fzd2 flox model does not fully delete Fzd2 function. To reconcile the contradictory findings in Fzd2 mouse models and allow for tissue-specific studies of Fzd2, we have generated a new flox model using a modified two-cell homologous recombination CRISPR approach. We demonstrated successful simultaneous insertion of two loxP sites fully surrounding the Fzd2 gene and confirmed cre-mediated recombination deletes the sequence between the loxP sites leading to a Fzd2 null allele. Preliminary studies suggest global knockouts are early embryonic lethal and full characterization of the tissue-specific effects of Fzd2 deletion is currently underway. This work suggests Fzd2 uniquely regulates development and emphasizes the importance of thorough validation of newly generated mouse models.
- Open Access
- 9 January 2019
- Published by SAGE Publications in Journal of Dental Research
- Vol. 98 (4) , 459-467
Clodronate-Loaded Liposome Treatment Has Site-Specific Skeletal Effects
Ineffective oral wound healing is detrimental to patients’ oral health–related quality of life. Delineating the cellular mechanisms involved in optimal healing will elicit better approaches to treating patients with compromised healing. Osteal macrophages have recently emerged as important positive regulators of bone turnover. The contributions of macrophages to long bone healing have been studied, but their role in oral osseous wound healing following tooth extraction is less clear. Clodronate-loaded liposomes were used as a tool to deplete macrophages in C57BL/6J mice and assess oral osseous bone fill after extraction. In addition to macrophage ablation, osteoclast ablation occurred. Interestingly, depletion of macrophages and osteoclasts via clodronate treatment had differential effects based on skeletal location. In the nonwounded tibiae, clodronate treatment significantly increased CD68+ cells and decreased F4/80+ cells in the marrow, which correlated with increased trabecular bone volume fraction after 7 and 14 d. Serum formation and resorptive markers P1NP and TRAcP 5b were decreased as were tibial TRAP+ osteoclasts. In healing extraction sockets, clodronate treatment increased extraction socket trabecular bone thickness at 14 d, which correlated with decreased TRAP+ osteoclasts and F4/80+ macrophages. Conversely, nonwounded maxillary interseptal bone was unaffected by clodronate treatment. Furthermore, the increase in extraction socket bone fill with clodronate was less than the large increase in trabecular bone observed in a nonwounded long bone. These data suggest a temporal and spatial specificity in the roles of macrophages and osteoclasts in normal turnover and healing.
- 9 January 2019
- Published by SAGE Publications in Journal of Dental Research
- Vol. 98 (4) , 459-467
Open AccessClodronate-Loaded Liposome Treatment Has Site-Specific Skeletal Effects
Ineffective oral wound healing is detrimental to patients’ oral health–related quality of life. Delineating the cellular mechanisms involved in optimal healing will elicit better approaches to treating patients with compromised healing. Osteal macrophages have recently emerged as important positive regulators of bone turnover. The contributions of macrophages to long bone healing have been studied, but their role in oral osseous wound healing following tooth extraction is less clear. Clodronate-loaded liposomes were used as a tool to deplete macrophages in C57BL/6J mice and assess oral osseous bone fill after extraction. In addition to macrophage ablation, osteoclast ablation occurred. Interestingly, depletion of macrophages and osteoclasts via clodronate treatment had differential effects based on skeletal location. In the nonwounded tibiae, clodronate treatment significantly increased CD68+ cells and decreased F4/80+ cells in the marrow, which correlated with increased trabecular bone volume fraction after 7 and 14 d. Serum formation and resorptive markers P1NP and TRAcP 5b were decreased as were tibial TRAP+ osteoclasts. In healing extraction sockets, clodronate treatment increased extraction socket trabecular bone thickness at 14 d, which correlated with decreased TRAP+ osteoclasts and F4/80+ macrophages. Conversely, nonwounded maxillary interseptal bone was unaffected by clodronate treatment. Furthermore, the increase in extraction socket bone fill with clodronate was less than the large increase in trabecular bone observed in a nonwounded long bone. These data suggest a temporal and spatial specificity in the roles of macrophages and osteoclasts in normal turnover and healing.
- Open Access
- 22 February 2018
- Published by Wiley in The FASEB Journal
- Vol. 32 (7) , 3730-3741
Inflammatory bone loss associated with MFG‐E8 deficiency is rescued by teriparatide
A prolonged increase in proinflammatory cytokines is associated with osteoporotic and autoimmune bone loss and, conversely, anti‐inflammatory pathways are associated with protection against bone loss. Milk fat globule‐epidermal growth factor (MFG‐E)‐8 is a glycoprotein that is proresolving, regulates apoptotic cell clearance, and has been linked to autoimmune disease and skeletal homeostasis. The role of MFG‐E8 in the young vs. adult skeleton was determined in mice deficient in MFG‐E8 (KO). In vivo , trabecular bone was similar in MFG‐E8KO and wild‐type (WT) mice at 6 and 16 wk, whereas 22 wk adult MFG‐E8KO mice displayed significantly reduced trabecular BV/TV. The number of osteoclasts per bone surface was increased in 22‐wk MFG‐E8 KO vs. WT mice, and recombinant murine MFG‐E8 decreased the number and size of osteoclasts in vitro. Adult MFG‐E8KO spleen weight:body weight was increased compared with WT, and flow cytometric analysis showed significantly increased myeloid‐derived suppressor cells (CD11b hi GR‐1 + ) and neutrophils (CD11b hi Ly6G + ) in MFG‐E8KO bone marrow, suggesting an inflammatory phenotype. PTH‐treated MFG‐E8KO mice showed a greater anabolic response (+124% BV/TV) than observed in PTH‐treated WT mice (+64% BV/TV). These data give insight into the role of MFG‐E8 in the adult skeleton and suggest that anabolic PTH may be a valuable therapeutic approach for autoimmune‐associated skeletal disease.—Michalski, M. N., Seydel, A. L., Siismets, E. M., Zweifler, L. E., Koh, A. J., Sinder, B. P., Aguirre, J. I., Atabai, K., Roca, H., McCauley, L. K. Inflammatory bone loss associated with MFG‐E8 deficiency is rescued by teriparatide. FASEB J. 32, 3730–3741 (2018). www.fasebj.org
- 22 February 2018
- Published by Wiley in The FASEB Journal
- Vol. 32 (7) , 3730-3741
Open AccessInflammatory bone loss associated with MFG‐E8 deficiency is rescued by teriparatide
A prolonged increase in proinflammatory cytokines is associated with osteoporotic and autoimmune bone loss and, conversely, anti‐inflammatory pathways are associated with protection against bone loss. Milk fat globule‐epidermal growth factor (MFG‐E)‐8 is a glycoprotein that is proresolving, regulates apoptotic cell clearance, and has been linked to autoimmune disease and skeletal homeostasis. The role of MFG‐E8 in the young vs. adult skeleton was determined in mice deficient in MFG‐E8 (KO). In vivo , trabecular bone was similar in MFG‐E8KO and wild‐type (WT) mice at 6 and 16 wk, whereas 22 wk adult MFG‐E8KO mice displayed significantly reduced trabecular BV/TV. The number of osteoclasts per bone surface was increased in 22‐wk MFG‐E8 KO vs. WT mice, and recombinant murine MFG‐E8 decreased the number and size of osteoclasts in vitro. Adult MFG‐E8KO spleen weight:body weight was increased compared with WT, and flow cytometric analysis showed significantly increased myeloid‐derived suppressor cells (CD11b hi GR‐1 + ) and neutrophils (CD11b hi Ly6G + ) in MFG‐E8KO bone marrow, suggesting an inflammatory phenotype. PTH‐treated MFG‐E8KO mice showed a greater anabolic response (+124% BV/TV) than observed in PTH‐treated WT mice (+64% BV/TV). These data give insight into the role of MFG‐E8 in the adult skeleton and suggest that anabolic PTH may be a valuable therapeutic approach for autoimmune‐associated skeletal disease.—Michalski, M. N., Seydel, A. L., Siismets, E. M., Zweifler, L. E., Koh, A. J., Sinder, B. P., Aguirre, J. I., Atabai, K., Roca, H., McCauley, L. K. Inflammatory bone loss associated with MFG‐E8 deficiency is rescued by teriparatide. FASEB J. 32, 3730–3741 (2018). www.fasebj.org